0.23p-0.02 (-9.41%)04 Jul 2025, 09:21
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Theracryf PLC Fundamentals

Company NameTheracryf PLCLast Updated2025-07-04
IndustryBiotechnologySectorHealthcare
Shares in Issue2.130 bnMarket Cap£4.92 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.2783Cash Equity Ratio0.6892
Quick Ratio2.7184Current Ratio3.11
Price To Book Value0.9098ROCE0

Theracryf PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Theracryf PLC Company Financials

Assets2025202420232022
Tangible Assets00£3,000.00£5,000.00
Intangible Assets£2.46 m£34,000.00£43,000.00£53,000.00
Investments0000
Total Fixed Assets£2.46 m£34,000.00£46,000.00£58,000.00
Stocks0000
Debtors£404,000.00£497,000.00£43,000.00£13,000.00
Cash & Equivalents£4.11 m£2.00 m£5.00 m£9.03 m
Other Assets0000
Total Assets£7.63 m£3.06 m£6.17 m£9.64 m
Liabilities2025202420232022
Creditors within 1 year£1.66 m£722,000.00£833,000.00£411,000.00
Creditors after 1 year-£1,000.00-£1,000.0000
Other Liabilities0000
Total Liabilities£1.66 m£721,000.00£833,000.00£411,000.00
Net assets£5.97 m£2.34 m£5.34 m£9.23 m
Equity2025202420232022
Called up share capital£5.32 m£687,000.00£687,000.00£687,000.00
Share Premium£28.70 m£27.87 m£27.87 m£27.87 m
Profit / Loss-£2.08 m-£3.57 m-£5.01 m-£3.17 m
Other Equity£5.97 m£2.34 m£5.34 m£9.23 m
Preference & Minorities0000
Total Capital Employed£5.97 m£2.34 m£5.34 m£9.23 m
Ratios2025202420232022
Debt Ratio0000
Debt-to-Equity0000
Assets / Equity1.27831.27831.27831.2783
Cash / Equity0.68920.68920.68920.6892
EPS£-0.00-£0.01-£0.01-£0.01
Cash Flow2025202420232022
Cash from operating activities-£2.37 m-£3.00 m-£4.13 m-£2.58 m
Cashflow before financing£2.18 m-£3.00 m00
Increase in Cash£105,000.00-£3.00 m£490,000.00-£1.08 m
Income2025202420232022
Turnover0£396,000.00£442,000.000
Cost of sales0000
Gross Profit0000
Operating Profit-£2.12 m-£3.57 m-£5.10 m-£3.19 m
Pre-Tax profit-£2.08 m-£3.57 m-£5.01 m-£3.17 m

Theracryf PLC Company Background

SectorHealthcare
ActivitiesTheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Latest Interim Date28 Nov 2024
Latest Fiscal Year End Date3 Jun 2025

Theracryf PLC Directors

AppointedNamePosition
2025-05-02Dr. Huw JonesExecutive Director,Chief Executive Officer
2025-02-19Dr. Susan Elizabeth FodenNon-Executive Director,Chairman
2017-06-23Mr. John BradshawExecutive Director,Finance Director and Company Secretary
2020-04-30Dr. Stephen Joseph FranklinExecutive Director,Chief Executive Officer
2024-05-30Mr. Richard Anthony MoulsonExecutive Director,Chief Financial Officer
2017-04-03Dr. Mark Andrew WyattNon-Executive Director
2023-09-05Mr. Barry ClareExecutive Director,Chairman
2018-11-08Dr. Marc Francois d’AbbadieNon-Executive Director
2025-05-02Dr. Alan John BargeNon-Executive Director,Senior Independent Director
2023-12-28Ms. Susan Elizabeth Clement-DaviesNon-Executive Director
2025-05-02Mr. Toni Markus Antero HanninenExecutive Director,Chief Financial Officer
2025-05-02Dr. Alastair Maclaughlin SmithNon-Executive Director,Chairman
2025-05-22Mr. Edward WardleNon-Executive Director

Theracryf PLC Contact Details

Company Name
Address
Telephone
Website

Theracryf PLC Advisors

AuditorRSM UK Audit LLP
Phone+44 1516002600
Remuneration ConsultantPricewaterhouseCoopers LLP
Phone+44 205835000
Fax+44 208224652
StockbrokerNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
RegistrarS.L.C Registrars Ltd
Phone+44 1903706150
Nominated AdviserNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
Financial PR AdviserBuchanan
Phone+44 2074665000
Fax+44 2074665001
SolicitorPinsent Masons LLP
Phone+44 2074187000
Fax+44 2074187050
SolicitorTheobald Associates
Phone+44 2073978434
Fax+44 2073978400
StockbrokerStockdale Securities Ltd
Phone+44 2076016100
Nominated AdviserStockdale Securities Ltd
Phone+44 2076016100